These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34532363)

  • 1. Cost-effectiveness analysis of camrelizumab in the second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Yang F; Fu Y; Kumar A; Chen M; Si L; Rojanasarot S
    Ann Transl Med; 2021 Aug; 9(15):1226. PubMed ID: 34532363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
    Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
    BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Camrelizumab
    Zhang Q; Wu P; He X; Ding Y; Shu Y
    Front Oncol; 2021; 11():790373. PubMed ID: 34926306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
    Lin YT; Chen Y; Liu TX; Kuang F; Huang P
    Cancer Manag Res; 2021; 13():8219-8230. PubMed ID: 34754242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of camrelizumab versus chemotherapy for the treatment of advanced or metastatic esophageal squamous cell carcinoma.
    Li L; Liu X; Huang J; Liu Y; Huang L; Feng Y
    J Gastrointest Oncol; 2022 Feb; 13(1):40-48. PubMed ID: 35284115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma.
    Cai H; Xu B; Li N; Zheng B; Zheng Z; Liu M
    Front Pharmacol; 2021; 12():732912. PubMed ID: 34867339
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma.
    Gong J; Shang J; Su D; Qian X; Liu G; Sun Z
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):709-717. PubMed ID: 37190977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.
    Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J
    BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis.
    Liu S; Zhao L; Shi F; Kuai L; Liu R; Tang J
    Int J Clin Pharm; 2024 Jun; 46(3):675-683. PubMed ID: 38407692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors
    Liu S; Dou L; Li S
    Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China.
    Dai H; Wang W; Fan X; Chen Y
    Front Med (Lausanne); 2023; 10():1122731. PubMed ID: 36865055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.
    Zhao Z; Chen T; Zhou Z; Guo R; Liu Q
    BMJ Open; 2023 Dec; 13(12):e071832. PubMed ID: 38110377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
    Shao T; Ren Y; Zhao M; Tang W
    Front Public Health; 2022; 10():912921. PubMed ID: 36045725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Shi F; He Z; Su H; Wang L; Han S
    Front Pharmacol; 2022; 13():961347. PubMed ID: 36467065
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
    Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
    Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma.
    You M; Huang Y; Cai Z; Wu Q; Zhu W; He Y; Chen R
    Front Oncol; 2022; 12():986762. PubMed ID: 36568254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Lin YT; Zhou CC; Xu K; Zhang MD; Li X
    Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China.
    Chen T; Xie R; Zhao Q; Cai H; Yang L
    Front Oncol; 2022; 12():746526. PubMed ID: 35936702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China.
    Qiao L; Zhou Z; Zeng X; Tan C
    Front Pharmacol; 2021; 12():728440. PubMed ID: 34795580
    [No Abstract]   [Full Text] [Related]  

  • 20. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lu S; Lou Y; Rong Y; Huang Z; Lin X; Chen J; Luo K
    Clin Drug Investig; 2023 Aug; 43(8):643-652. PubMed ID: 37542611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.